INTRAVITREAL INJECTION OF MICROPLASMIN FOR TREATMENT OF VITREOMACULAR ADHESIONстатья из журнала
Аннотация: In Brief Purpose: Vitreomacular adhesion causing vitreomacular traction is a common indication for vitrectomy. It may be avoided by using enzymatic vitreolysis. The MIVI-IIT (traction) study evaluated the ability of a single or repeated injection of microplasmin to release vitreomacular traction. Methods: This randomized, double-masked, Phase II trial with control sham injection enrolled 60 patients. Patients in each of the 4 cohorts were randomized (4:1) to active treatment or sham injection. In the first 3 cohorts, increasing doses of microplasmin (75, 125, and 175 μg) were administered. In the fourth cohort, an initial injection of 125 μg microplasmin or sham was administered followed 1 month later by an injection of 125 μg microplasmin if no release of adhesion occurred. A third dose was injected 4 weeks later if there was still no release of adhesion. Results: Within 28 days of sham, 75, 125, and 175 μg microplasmin administration, nonsurgical resolution of vitreomacular adhesion was observed in 8, 25, 44, and 27% of the patients, respectively. When the 125 μg dose was repeated up to 3 times, adhesion release was observed in 58% of patients 28 days after the final injection. Conclusion: These results provide support for the potential of microplasmin as a nonsurgical treatment for vitreomacular adhesion. Patients with vitreomacular adhesion received a single intravitreal injection (75, 125, or 175 μg) or sham injection or up to 3 repeat intravitreal injections (125 μg) of microplasmin. Resolution of adhesion was found in up to 44% of patients within 1 month after a single injection and in 58% after multiple injections.
Год издания: 2010
Издательство: Lippincott Williams & Wilkins
Источник: Retina
Ключевые слова: Retinal and Macular Surgery, Intraocular Surgery and Lenses, Vascular Malformations Diagnosis and Treatment
Открытый доступ: closed
Том: 30
Выпуск: 7
Страницы: 1122–1127